CSBio CSBio

X
[{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xellia Pharmaceuticals expands approved doses of VANCO READY\u2122 (Ready-to-use Premixed Vancomycin bags)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Xellia Pharmaceuticals ApS"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Positive Topline Results from Phase 3 Clinical Study of Freeze-dried Smallpox Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Health Emergency Preparedness and Response Authority","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Enters Vaccine Supply Contract with the European Health Emergency Preparedness and Response Authority (HERA) in Response to Monkeypox Outbreak","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"U.S. Department of Health and Human Services","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"HHS Orders 2.5 Million More Doses of JYNNEOS Vaccine For Monkeypox Preparedness","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include Monkeypox","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"HERA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Enters Joint Procurement Agreement with the European Health Emergency Preparedness and Response Authority (HERA) for Monkeypox Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Danske Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic A\/S Launches Offering of up to 7,046,839 New Shares in a Directed Issue","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"European Union","pharmaFlowCategory":"D","amount":"$11.8 million","upfrontCash":"Undisclosed","newsHeadline":"Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic\u2019s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Vaccine","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) is approved for the prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox and mpox infection.

            Lead Product(s): Live Nonreplicating Smallpox and Monkeypox Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Jynneos

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 25, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Bavarian will supply its Imvanex (MVA-BN or modified vaccinia ankara ) non-replicating smallpox vaccine to rescEU, a strategic reserve within the European Union.

            Lead Product(s): Modified Vaccinia Ankara

            Therapeutic Area: Infections and Infectious Diseases Product Name: Imvanex

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: European Union

            Deal Size: $11.8 million Upfront Cash: Undisclosed

            Deal Type: Agreement September 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The net proceeds from the Offering are intended to be used for payment of the purchase price in respect of the Company’s contemplated acquisition of a portfolio of travel vaccines including Vivotif (typhoid vaccine) from Emergent BioSolutions.

            Lead Product(s): Typhoid Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Vivotif

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Danske Bank

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Private Placement February 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government.

            Lead Product(s): MVA-BN

            Therapeutic Area: Infections and Infectious Diseases Product Name: Imvanex

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: HERA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IMVANEX® (MVA-BN) is a non-replicating smallpox vaccine, to ensure supply of smallpox vaccine for entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines.

            Lead Product(s): MVA-BN

            Therapeutic Area: Infections and Infectious Diseases Product Name: Imvanex

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IMVANEX® (MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic) is a non-replicating smallpox vaccine, that is extended to include protecting people from monkeypox disease.

            Lead Product(s): MVA-BN

            Therapeutic Area: Infections and Infectious Diseases Product Name: Imvanex

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BARDA supported the development of JYNNEOS, which is approved by the FDA to prevent smallpox and monkeypox. The U.S. government owns enough smallpox vaccine – JYNNEOS and ACAM2000 – to vaccinate millions of Americans.

            Lead Product(s): Live Nonreplicating Smallpox and Monkeypox Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Jynneos

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: U.S. Department of Health and Human Services

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            MVA-BN or Modified Vaccinia Ankara (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population.

            Lead Product(s): MVA-BN

            Therapeutic Area: Infections and Infectious Diseases Product Name: IMVANEX

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Health Emergency Preparedness and Response Authority

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bavarian Nordic’s smallpox vaccine is approved in the U.S as JYNNEOS and in Canada as IMVAMUNE, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe as IMVANEX (Live Modified Vaccinia Virus Ankara) for smallpox indication.

            Lead Product(s): Live Modified Vaccinia Virus Ankara

            Therapeutic Area: Infections and Infectious Diseases Product Name: Imvanex

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 19, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            MVA-BN, (Modified Vaccinia Ankara - Bavarian Nordic) is a proprietary and patented vaccine platform technology, robust and adaptable platform suitable for addressing a wide variety of infectious diseases and cancers.

            Lead Product(s): MVA-BN

            Therapeutic Area: Infections and Infectious Diseases Product Name: Imvanex

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY